Technological Incubators


Jerusalem 91450
Bookmark and Share
Company Profile

BioLineRx is a clinical-stage, publicly-traded, (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel.
The Company's declared aim is to develop products suitable for today's pharmaceutical market satisfying an unmet medical need or exhibiting features and benefits above those of current therapies.
BioLineRx's close ties to technology transfer offices,...Read more
Company News
March 7, 2012 Latest Press Releases
BioLineRx Announces Grant of European Patent Covering BL-1020, an Orally Available Treatment for Schizophrenia
March 5, 2012 Latest Press Releases
BioLineRx Receives Approval for Commencing Phase II Clinical Trial of BL-7040, an Orally Available Treatment for Inflammatory Bowel Disease
Our development pipeline consists of five clinical therapeutic candidates:
BL1020, an orally available, first in class antipsychotic indicated for the treatment of schizophrenia (Phase II/III commenced);
BL1040, a medical device developed for the prevention of cardiac remodeling in Acute Myocardial Infarction patients (Phase I/II clinical trial completed, CE Mark Registration trial commenced);
BL5010, a novel formulation for non surgical removal of skin lesions (Phase I/II clinical trial completed);
BL1021, a new chemical entity for neuropathic pain ( Phase I) and BL7040, a novel, orally available synthetic oligonucleotide for the treatment of inflammatory bowel disease (phase II commencing).
Thirteen additional compounds are currently in the pipeline at various stages of pre-clinical development.

Terms of Use
Legal Liability
Site Map
© All rights reserved to IsraelExporter